Background: Intermittent fasting emerges as a promising dietary approach against obesity, offering a cost-effective strategy for implementation via web-based platforms. We developed a Brief Online Intermittent Fasting Program (OIF), featuring a self-administered, weekly 1-day…
Continue Reading
We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guests today are Jamie Luu, RDN, LDN, Strategy and Nutrition Manager, and Ronja Krieger, Chief…
Continue Reading
What You Should Know
– Amazon Pharmacy has officially added Novo Nordisk’s Wegovy® pill—the first and only FDA-approved oral GLP-1 for weight management—to its nationwide delivery platform.
– To lower barriers to care, Amazon is offering…
Continue Reading
We evaluated the effectiveness of a low-carbohydrate digitally-supported weight loss programme for glycaemic control for people with type 2 diabetes (T2D) compared with usual primary care in a 12 month RCT. We individually randomised…
Continue Reading
What You Should Know:
– GoodRx has unveiled two major initiatives to democratize access to GLP-1 medications: the launch of the GoodRx for Weight Loss telemedicine subscription and a new introductory cash price of $199…
Continue Reading
Introduction
In a groundbreaking move that reshapes direct-to-consumer pharmaceutical access, Eli Lilly has partnered with Walmart to offer in-store pickup services for Zepbound vials. This collaboration represents the first retail pharmacy partnership for LillyDirect, Eli…
Background: Intensive lifestyle interventions (ILI) improve weight loss and cardiovascular risk factors, but health systems face challenges implementing them. Objective: We engaged stakeholders to cocreate and evaluate feasibility of primary care implementation strategies and…
Continue Reading
Dr. Robyn Daugherty, a double board-certified female plastic surgeon and founder of Daugherty Plastic Surgery in Baton Rouge, LA again joins eHealth Radio and the Plastic Surgery Information Channel. She specializes in aesthetic procedures…
Continue Reading
What You Should Know:
– Eli Lilly and Company has announced positive topline results from its Phase 3 ATTAIN-2 trial, which evaluated orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight…
Continue Reading
Background: Overweight and obesity have become a public health issue. Lifestyle modifications delivered through mobile devices, especially mobile phones, present an opportunity to support weight loss efforts. However, evidence regarding the effects of mobile…
Continue Reading
